HLA-A*0201 & B2M & p53 (HMTEVVRHC)
HLA-A*0201 & B2M & p53 (HMTEVVRHC) Produktliste
- Attribut
Protein (2)
- Produktbibliothek
Online (2)
- Spezies
Human (2)
- Etikett
His Tag & Avi Tag (1)His Tag (1)
- Marker
Biotin-labeled (1)PE Labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (Monomer, MALS verified) |  |  |  In den Warenkorb legen | ||
| Human | HEK293 | PE-Labeled Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Tetramer Protein | | In den Warenkorb legen |
Gesamtmenge2
- 1
HLA-A*0201 & B2M & p53 (HMTEVVRHC) Molekülhintergrund
TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRHC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRHC peptide of the p53.
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Superoxide dismutase (Ube Industries) | r-hSOD; FKU-871 | Phase 2 Clinical | Ube Industries Ltd, Astellas Pharma Inc | Myocardial Ischemia; Diabetic Neuropathies | Details |
| Otaplimastat | SP-8203 hydrochloride; SP8203 HCL; SP-8203 | Phase 2 Clinical | Shin Poong Pharmaceutical Co Ltd | Stroke | Details |
| BMX-010 | BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ | Phase 2 Clinical | Duke University | Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic | Details |
| APB-102 | APB-102; AMT-162 | Phase 2 Clinical | University Of Massachusetts Medical School | Amyotrophic Lateral Sclerosis | Details |
| Rucosopasem manganese | GC-4711 | Phase 1 Clinical | Galera Therapeutics Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bis-choline tetrathiomolybdate | ATN-224; WTX-101; ALXN-1840 | Phase 1 Clinical | Wilson Therapeutics | Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma | Details |
| NAS150 | AEOL-10150; NAS150; NAS-150 | Phase 1 Clinical | Aeolus Pharmaceuticals | Supranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury | Details |
| RAG-17 | RAG-17; RAG17 | Phase 1 Clinical | Amyotrophic Lateral Sclerosis | Details | |
| NI-005 | AP-101 (AL-S Pharma); NI-005 | Phase 1 Clinical | Al-S Pharma Ag | Amyotrophic Lateral Sclerosis | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Orgotein | Approved | Gt Biopharma Inc | Ontosein | Spain | Rheumatic Diseases; Cystitis; Radiation Injuries | null | 1996-01-01 | Cystitis; Radiation Injuries; Rheumatic Diseases | Details | |
| Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate | Approved | American Regent Inc | MULTRYS | United States | Dietary Supplement | American Regent Inc | 2020-07-02 | Dietary Supplement | Details | |
| Tofersen | ISIS-333611; BIIB-067; 99mTc-MAG3-BIIB067 | Approved | Ludwig Institute For Cancer Research, Ionis Pharmaceuticals Inc | QALSODY | United States | Amyotrophic Lateral Sclerosis | Biogen Ma Inc, Biogen Inc | 2023-04-25 | Amyotrophic Lateral Sclerosis | Details |
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation